Capital Advisors Ltd’s AstraZeneca AZN Stock Holding History

Capital Advisors Ltd’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,158	Closed	-$81K	–	398
2018 Q1	$81K	Hold	1,158	–	–	0.03%	189
2017 Q4	$80K	Hold	1,158	–	–	0.03%	187
2017 Q3	$78K	Hold	1,158	–	–	0.03%	183
2017 Q2	$79K	Hold	1,158	–	–	0.03%	179
2017 Q1	$72K	Hold	1,158	–	–	0.03%	173
2016 Q4	$63K	Hold	1,158	–	–	0.03%	173
2016 Q3	$76K	Hold	1,158	–	–	0.03%	163
2016 Q2	$70K	Hold	1,158	–	–	0.03%	162
2016 Q1	$65K	Hold	1,158	–	–	0.03%	165
2015 Q4	$79K	Hold	1,158	–	–	0.04%	155
2015 Q3	$74K	Hold	1,158	–	–	0.04%	156
2015 Q2	$74K	Hold	1,158	–	–	0.04%	155
2015 Q1	$79K	Hold	1,158	–	–	0.04%	155
2014 Q4	$82K	Hold	1,158	–	–	0.04%	140
2014 Q3	$82K	Hold	1,158	–	–	0.05%	144
2014 Q2	$86K	Hold	1,158	–	–	0.05%	148
2014 Q1	$75K	Buy	+1,158	New	+$74.8K	0.04%	152

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Capital Advisors Ltd's AZN Position: Q2 2018 in Review

Capital Advisors Ltd sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 1,158 shares — an estimated $81K sold.

Capital Advisors Ltd first reported a position in AZN in Q1 2014 and held it in 17 quarters. The position peaked at $86K in Q2 2014. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Capital Advisors Ltd reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
Capital Advisors Ltd sold 1,158 AstraZeneca shares in Q2 2018, an estimated $81K.
Capital Advisors Ltd first reported a position in AstraZeneca in Q1 2014 and held it in 17 quarters.
Capital Advisors Ltd's AstraZeneca position peaked at $86K in Q2 2014.
530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Capital Advisors Ltd's 13F filing for Q2 2018, filed 20 Jul 2018.